Sfoglia per Autore "Tassopoulos, N."
Items 1-3 di 3
-
Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C
Gatselis, N. K.; Georgiadou, S. P.; Koukoulis, G. K.; Tassopoulos, N.; Zachou, K.; Liaskos, C.; Hatzakis, A.; Dalekos, G. N. (2006)Background: Development of organ- and non-organ-specific autoantibodies has been reported in hepatitis C virus patients treated with interferon-α plus/minus ribavirin. Aims: To address whether prevalence and the titre of ... -
Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study
Anagnostou, O.; Manolakopoulos, S.; Bakoyannis, G.; Papatheodoridis, G.; Zisouli, A.; Raptopoulou-Gigi, M.; Manesis, E.; Ketikoglou, I.; Dalekos, G.; Gogos, C.; Vassiliadis, T.; Tzourmakliotis, D.; Karatapanis, S.; Kanatakis, S.; Zoumpoulis-Vafiadis, I.; Hounta, A.; Koutsounas, S.; Giannoulis, G.; Tassopoulos, N.; Touloumi, G. (2014)Background and aim: Patients with genotype 4 (G4) chronic hepatitis C (CHC) are considered a difficult to treat population, although current data on G4 treatment responsiveness and duration are controversial. Greece ... -
Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study
Gatselis, N. K.; Georgiadou, S. P.; Tassopoulos, N.; Zachou, K.; Liaskos, C.; Hatzakis, A.; Dalekos, G. N. (2005)AIM: Various side effects have been reported in patients infected with hepatitis C virus (HCV) who were treated with interferon-alpha (IFN-alpha), including the appearance or exacerbation of underlying autoimmune diseases ...